regulatory
confidence high
sentiment positive
materiality 0.90
FDA approves first CRISPR therapy, CASGEVY; Vertex to pay CRSP $200M milestone
CRISPR Therapeutics AG
- FDA approved CASGEVY (exagamglogene autotemcel) for sickle cell disease in patients 12+ with recurrent vaso-occlusive crises.
- Vertex set wholesale acquisition cost at $2.2 million for CASGEVY in the U.S.
- Approval triggered Vertex's $200 million milestone payment to CRISPR Therapeutics under the joint development agreement.
- This is the first-ever FDA approval of a CRISPR-based gene-editing therapy.